Aligos Therapeutics (NASDAQ:ALGS) Raised to Strong-Buy at Jefferies Financial Group

Aligos Therapeutics (NASDAQ:ALGS) was upgraded by stock analysts at Jefferies Financial Group to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

Several other research analysts have also recently issued reports on the stock. Westpark Capital assumed coverage on shares of Aligos Therapeutics in a report on Thursday. They set a “buy” rating and a $48.00 target price on the stock. UBS Group started coverage on shares of Aligos Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 price target for the company. Wall Street Zen downgraded shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Wednesday, January 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Aligos Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $41.50.

Aligos Therapeutics Stock Down 5.4%

Shares of NASDAQ ALGS opened at $6.66 on Thursday. The business has a fifty day simple moving average of $7.30 and a two-hundred day simple moving average of $8.72. The firm has a market cap of $41.23 million, a PE ratio of -0.78 and a beta of 2.67. Aligos Therapeutics has a twelve month low of $3.76 and a twelve month high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.09) by $0.18. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%. On average, research analysts expect that Aligos Therapeutics will post -10.36 earnings per share for the current year.

Institutional Trading of Aligos Therapeutics

Several hedge funds have recently modified their holdings of ALGS. NorthCrest Asset Manangement LLC bought a new stake in shares of Aligos Therapeutics in the 3rd quarter valued at about $98,000. Rockefeller Capital Management L.P. raised its stake in shares of Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after acquiring an additional 9,000 shares in the last quarter. Susquehanna International Group LLP bought a new position in shares of Aligos Therapeutics during the 3rd quarter worth approximately $99,000. HRT Financial LP purchased a new stake in Aligos Therapeutics during the fourth quarter valued at approximately $106,000. Finally, DRW Securities LLC purchased a new stake in Aligos Therapeutics during the fourth quarter valued at approximately $111,000. 60.43% of the stock is owned by hedge funds and other institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.